Last $39.30 USD
Change Today -0.34 / -0.86%
Volume 2.8M
TEVA On Other Exchanges
Symbol
Exchange
New York
OTC US
Tel Aviv
Frankfurt
Mexico
As of 8:04 PM 06/19/13 All times are local (Market data is delayed by at least 15 minutes).

teva pharmaceutical-sp adr (TEVA) Snapshot

Open
$39.72
Previous Close
$39.64
Day High
$39.72
Day Low
$39.16
52 Week High
12/10/12 - $42.83
52 Week Low
12/31/12 - $36.63
Market Cap
33.4B
Average Volume 10 Days
3.9M
EPS TTM
--
Shares Outstanding
851.0M
EX-Date
05/16/13
P/E TM
--
Dividend
$1.26
Dividend Yield
2.88%
Current Stock Chart for TEVA PHARMACEUTICAL-SP ADR (TEVA)

teva pharmaceutical-sp adr (TEVA) Details

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. It offers generic pharmaceutical products; and basic chemical entities, as well as specialized product families, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances. The company’s principal branded pharmaceutical products comprise Copaxone for multiple sclerosis; Provigil and Nuvigil for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorders; Azilect for the treatment of Parkinson’s disease; Fentora and Actiq for the treatment of pain in opioid-tolerant adult patients with cancer; Amrix for muscle spasm in acute, painful, and musculoskeletal conditions; ProAir for the treatment of bronchial spasms; Qvar for long-term control of chronic bronchial asthma; and Qnasl Nasal Aerosol for seasonal nasal and year-round nasal allergy symptoms. The company also offers Treanda for the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma; Tevagrastim/Ratiograstim that stimulate the production of white blood cells; Eporatio, which stimulates the production of red blood cells; Synribo for chronic myeloid leukemia; Plan B One-Step for emergency oral contraception; ParaGard, a non hormonal intrauterine contraceptive; hormone therapies for menopause/perimenopause; Enjuvia for vasomotor symptoms associated with menopause; and therapies for infertility and urinary incontinence. In addition, it produces active pharmaceutical ingredients in the areas of respiratory, cardiovascular, anti-cholesterol, central nervous system, dermatological, hormones, anti-inflammatory, oncology, immunosuppressants, and muscle relaxants. Further, the company distributes third party products. It has collaborative agreements with Lonza Group Ltd. and OncoGenex Pharmaceuticals, Inc. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.

45,948 Employees
Last Reported Date: 02/12/13
Founded in 1901

teva pharmaceutical-sp adr (TEVA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

teva pharmaceutical-sp adr (TEVA) Key Developments

Teva Pharmaceutical Industries Limited and Active Biotech AB Report Positive Results from Phase IIa Study of Laquinimod in Active Lupus Nephritis

Teva Pharmaceutical Industries Limited and Active Biotech announced the results of a Phase IIa study of oral laquinimod designed to assess safety, tolerability and clinical efficacy in patients with active lupus nephritis, one of the most serious manifestations of systemic lupus erythematosus (SLE or lupus)that can lead to chronic kidney failure. Treatment with laquinimod provided an additive effect in improving renal function when combined with current standard of care for active lupus nephritis (mycophenolate mofetil and corticosteroids), compared with standard of care alone. The data will be presented during the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in Madrid, 12-15 June, 2013 as part of the late-breaking news session. The clinical trial, NCT01085097, was a multicenter, double-blind, placebo-controlled, exploratory study of 46 patients with active lupus nephritis that evaluated oral laquinimod (0.5 and 1mg/day) versus placebo in combination with standard of care treatment. The study showed that at 24 weeks, 62.5% of patients with active lupus nephritis who received 0.5mg/day of laquinimod achieved renal response, compared to 33.3% of patients who were administered placebo. Renal response is a composite end point that measures several parameters of renal improvement.

Teva Pharmaceutical Industries Limited Reaches Settlement Agreement with Pfizer and Nycomed Regarding Generic Protonix(R) (Pantoprazole) Tablets

Teva Pharmaceutical Industries Limited announced that it has entered into a settlement agreement with Wyeth/Pfizer and Altana/Nycomed to resolve all claims relating to Teva's sales, commencing in December 2007, of its 20 mg and 40 mg generic Protonix(R) (pantoprazole sodium) tablets. As part of the settlement, which provides for the release of all claims against Teva and its subsidiaries, Teva agreed to pay $1.6 billion to Wyeth/Pfizer and Altana/Nycomed. Teva will pay $800 million in 2013 and the remainder in 2014. As a result of this settlement, Teva expects to incur a charge of approximately $930 million in the second quarter of 2013 in addition to the $670 million provision previously recorded in its 2012 financial statements. The Company believes it may have up to $560 million of net insurance coverage in connection with this settlement, subject to recovery from the insurance carriers.

Pfizer Obtains $2.15 Billion Settlement from Teva and Sun for Infringement of Protonix Patent

Pfizer Inc. announced a $2.15 billion settlement reached with Teva Pharmaceuticals Industries, Limited and Sun Pharmaceutical Industries, Limited for patent-infringement damages resulting from their at-risk launches of generic Protonix in the United States. The settlement comes after a nearly 10-year legal battle in which Pfizer and Nycomed sought to enforce the patent for its blockbuster acid reflux medicine. Pfizer and Takeda will divide the proceeds of the settlement with Pfizer receiving 64%. Under the terms of the settlement, Teva and Sun will pay a total of $2.15 billion to compensate Pfizer's subsidiary Wyeth and Takeda for the damages they suffered when Teva and Sun launched "at-risk" generic versions of Protonix prior to the January 2011 expiry of the patent for pantoprazole, the active ingredient in Protonix. These "at-risk" launches were determined by a jury in New Jersey federal court to violate United States Patent No. 4,758,579, which is owned by Takeda and was licensed exclusively to Wyeth in the United States. The parties reached the settlement shortly after the commencement of a trial to determine damages in the same New Jersey federal court. Teva will pay Pfizer and Takeda $1.6 billion and Sun will pay $550 million. Teva will pay $800 million in 2013 and the remaining $800 million by October 2014; Sun's entire payment will be made in 2013. As part of the settlement, both Teva and Sun have admitted that their sales of generic pantoprazole infringed the patent that was held valid by the court.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVA:US $39.30 USD -0.34

TEVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $43.04 USD -0.50
Baxter International Inc $69.66 USD -1.22
Covidien PLC $63.57 USD -2.37
Eli Lilly & Co $51.37 USD -0.98
Johnson Matthey PLC 2,632 GBp +2.00
View Industry Companies
 

Industry Analysis

TEVA

Industry Average

Valuation TEVA Industry Range
Price/Earnings 19.8x
Price/Sales 1.7x
Price/Book 1.5x
Price/Cash Flow 21.6x
TEV/Sales 1.2x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL-SP ADR, please visit www.tevapharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.